KORRO BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.93 USD | +7.52% |
|
-5.71% | +31.30% |
| Apr. 24 | Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing | MT |
| Apr. 24 | Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 383.3 | 583.5 | - | - |
| Enterprise Value (EV) 1 | 383.3 | 583.5 | 583.5 | 583.5 |
| P/E ratio | -0.9 x | -6.59 x | -6.58 x | -8.44 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -5.1 x | -6.67 x | -6.14 x | -5.67 x |
| FCF Yield | -19.6% | -15% | -16.3% | -17.7% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 7,997 | 9,273 | - | - |
| Reference price 2 | 47.93 | 62.93 | 62.93 | 62.93 |
| Announcement Date | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -84.53 | -85.92 | -89.97 | -93.04 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -58.02 | -81.14 | -83.6 | -88.98 | -93.04 |
| Net income 1 | -58.03 | -81.17 | -83.6 | -88.98 | -93.04 |
| Net margin | - | - | - | - | - |
| EPS 2 | - | -53.08 | -9.543 | -9.557 | -7.460 |
| Free Cash Flow 1 | - | -75.12 | -87.5 | -95 | -103 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/27/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -26.89 | -21 | -21.75 | -22 | -22.25 | -21 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -25.4 | -19.96 | -20.82 | -21.19 | -21.56 | -21 |
| Net income 1 | -25.43 | -19.96 | -20.82 | -21.19 | -21.56 | -21 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -43.10 | -2.510 | -2.570 | -2.630 | -2.690 | -2.660 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -75.1 | -87.5 | -95 | -103 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 7.84 | 5 | 5 | 6 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 7/27/23 | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
62.93
USD
Average target price
130
USD
Spread / Average Target
+106.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.30% | 584M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- KRRO Stock
- Financials Korro Bio, Inc.
